BioSpace

Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reported data bolstering its case to bring to market the first CAR T for an autoimmune disease.

بقلم BioSpace

1 دقيقة قراءة
مشاركة
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

هل لديك أخبار لمشاركتها مع صناعة الفعاليات؟

أرسل بياناً صحفياً أو تلميحاً بقصة وتواصل مع آلاف المهنيين في مجال الفعاليات.

تواصل معنا→

المزيد في Health Tech

رؤى ذات صلة